Hikma Pharmaceuticals PLC Annual Report 2014 HOW WE PERFORMED IN 2014 Another excellent year Hikma delivered strong revenue and earnings growth 1 2014 REVENUE 2009-14 REVENUE CAGR 2014 ADJUSTED OPERATING MARGIN $1,489m 19% 28.7% 2014 PRODUCTS MARKETED 2014 OPERATING CASH FLOW 2014 EMPLOYEES 582 $425m 7,248 2014 REVENUE BY SEGMENT % 2014 REVENUE BY REGION % 1 1 3 3 2 2 1.
Europe and rest of the world 6% 1 Before the amortisation of intangible assets excluding software and exceptional items, as set out in Note 5 to the consolidated financial statements 12 Strategic report 1 REVENUE $ MILLION ADJUSTED OPERATING PROFIT $ MILLION 9% in 2014 3% in 2014 2014 1,489 2014 427 2013 1,365 2013 413 2012 1,109 2012 194 PROFIT ATTRIBUTABLE 2 EBITDA $ MILLION TO SHAREHOLDERS $ MILLION 11% in 2014 31% in 2014 2014 474 2014 278 2013 427 2013 212 2012 226 2012 100 3 DIVIDEND PER SHARE CENTS BASIC EARNINGS PER SHARE CENTS 10% in 2014 30% in 2014 2014 22.0 2014 140.4 2013 20.0 2013 107.6 2012 16.0 2012 51.1 1 Before the amortisation of intangible assets excluding software and exceptional items, as set out in Note 5 to the consolidated financial statements 2 Earnings before interest, tax, depreciation and amortisation.
EBITDA is stated before impairment charges and share of results from associated companies 3 In addition, the Board has recommended a special full year dividend of 10.0 cents per share in 2014 2013: 7.0 cents to reflect the excellent performance of the Group in 2014 13
